Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Jay Brown, Human Rights Campaign Foundation's Senior Vice President of Programs, Research and Training on the importance of recognizing Pride Month and the fight for equality for all.
Pride started with protest. At places like the Black Cat, Compton’s Cafeteria and Stonewall, LGBTQ pioneers – led by Black and Brown transgender women – pushed back against police harassment and violence. It’s with this history that we recognized our pride this month and also joined the protests demanding justice for George Floyd, Breonna Taylor, Brianna “BB” Hill and far too many others. It’s with this history we celebrated the Supreme Court victories protecting LGBTQ workers and DACA dreamers. And it’s with this history that we doubled down on the work ahead, as we face the dual pandemics of COVID-19 and racism, which disproportionately impact LGBTQ people of color.
As COVID-19 emerged, the Human Rights Campaign (HRC) Foundation released a research brief warning that the epidemic would hit LGBTQ people, and particularly LGBTQ people of color and transgender people, particularly hard. The HRC Foundation and PSB Research released data bearing out these initial predictions. The LGBTQ community is as diverse as the fabric of this nation. And we have seen time and again that LGBTQ people who sit at the intersection of multiple marginalized identities often face the greatest injustice. It is imperative that we continue to fight for the resources to ensure that communities most impacted can weather this storm.
This work cannot happen without clear and explicit protections under federal law – protections not only for workers but for patients and students and home buyers and jurors. That is why HRC, alongside a broad chorus of nearly 300 corporations like PhRMA, is calling on the U.S. Senate to pass the Equality Act – which would codify comprehensive protections for LGBTQ people under federal law.
We must also do more to create inclusive health care settings, so marginalized people seeking medical help for COVID-19 aren’t being faced with obstacles that others may not face. There are great strides to be made in making every waiting room, doctor’s office, pharmacy and hospital room is LGBTQ-inclusive. That’s why HRC launched the Healthcare Equality Index (HEI) over a decade ago, which PhRMA has also supported over the years. This national LGBTQ benchmarking tool evaluates health care facilities' policies and practices related to the equity and inclusion of their LGBTQ patients, visitors and employees. Our most recent HEI evaluated more than 1,600 health care facilities nationwide. In addition to being a valuable tool and resource for health care facilities, the HEI is used by LGBTQ patients and their loved ones to find facilities that provide equitable and inclusive care.
And because we know that the gap between legal equality and lived equality is profound, it’s why we won’t stop our work in the HRC Foundation to push for changes in policies, practices and hearts and minds. Through our Corporate Equality Index, we’ll continue to push for more inclusive policies for LGBTQ workers. Our Long-Care Equality Index, in partnership with SAGE, will help foster safe communities for LGBTQ elders. Our Welcoming Schools and HBCU programs will build safer school climates for LGBTQ young people. And our HIV & Health Equity program won’t stop their efforts to address barriers to prevention, testing and treatment access until the HIV epidemic – another epidemic that has disproportionately impacted Black and Latinx LGBTQ people – is finally over. Through nearly a dozen programs and initiatives, we will work for LGBTQ people to be valued not just under law, but in our daily lives.
This work cannot happen alone. Together, we can learn, teach, activate and ensure that our most marginalized populations no longer have to fear if who they are or who they love are barriers to their health and safety. Together we can close that gap between legal equality and lived equality once and for all.
An experienced non-profit leader with nearly 20 years of experience, Jay Brown drives the innovative work of the HRC Foundation, the organization’s educational arm. As the Senior Vice President of Programs, Research and Training, he works with a team of professionals who manage HRC Foundation programs -- aiming to ensure equality for LGBTQ people at every intersection of their identities and lives. These programs span a range of issues, including the workplace; children, youth and LGBTQ families; health and aging; HIV and AIDS; religion and faith; and the global LGBTQ movement.
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
Recent events highlight progress on health equity
ICYMI: PhRMA’s 4th Annual Pathways to Success: Virtual STEM Career Expo
Hispanic Heritage Month: Fighting for Hispanic patients
PhRMA awards grants to 2024 Annual Pathways to Success: Virtual STEM Career Expo Partners
How government price setting fails to address systemic health care inequities
Women’s Health Month: A conversation with Sage
Championing cancer equity: Our drive for healthier AANHPI communities
New analysis: Accelerated approval pathway is changing lives in underserved communities
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
PhRMA provides grant funding to support the Morehouse School of Medicine Satcher Health Leadership Institute’s Health Equity Tra
WHO Pandemic Agreement offers opportunities and risks for American innovators
New social determinants of health simulation explores structural barriers patients face accessing and affording medicines
What you should know about protecting your health this fall
PhRMA awards grants to 2023 Annual Pathways to Success Graduate Summit Partners
What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain
Key considerations as Congress works towards PAHPA reauthorization
Between hope and despair: Improving cancer outcomes
A conversation with Dr. Mike Ybarra on the current state of COVID-19
PhRMA awards grant to Emerson Diversity Health Foundation
PhRMA Otorga Beca a la “Emerson Diversity Health Foundation”
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
Celebrating the success of the COVID-19 vaccines, and looking to the future
PhRMA submits comments to OSTP on enhancing clinical trial diversity
What we’ve learned from three years of fighting COVID-19
U.S. must address IP and market access barriers abroad to protect American innovation
Using traditional HTAs to determine coverage threatens patient access to medicine
Traditional HTAs keep diverse patients out of the conversation
Word of the Month: What is TRIPS?
TRIPS waiver expansion risks public health
Expanding the WTO intellectual property waiver will hurt American jobs
Traditional HTA methods treat everyone like the “average” patient
Word of the Month: Long COVID
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
Partnerships are driving global COVID-19 treatment access
The dangers of expanding the TRIPS waiver
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
Potential gene therapies bring hope to patients with sickle cell disease
Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
A conversation with Barry Greene, CEO of Sage Therapeutics
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19
Stephanie Dyson of BMS on reducing health disparities
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
What you need to know about newly authorized COVID-19 antiviral treatments
Guest post: Joining forces to combat the COVID-19 mental health crisis
Guest Blog: COVID-19 vaccines are the key to keeping kids healthy
Protecting U.S. innovation abroad to support economic and pandemic recovery
ICYMI: New report demonstrates growing global impact of antimicrobial resistance
Navigating the patient experience in the time of COVID-19
Global COVID-19 vaccination matters now and for the future
Announcing CAREs Grant Round 4
Announcing CAREs Grant Round 4
Understanding breakthrough COVID-19 infections
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19
The important role of antivirals in the fight against COVID-19
Understanding Long COVID-19
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
The impact of monoclonal antibodies and COVID-19 recovery
Recognizing National Immunization Awareness Month
Driving further innovation is critical to global vaccine equity
Supporting country readiness to boost global vaccine access
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine
Increasing global access to vaccines by optimizing production
Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief
Guest Post: A patient’s story of the long-term health impacts of COVID-19
Dose sharing as a part of the COVID-19 global vaccine equity strategy
Promoting global vaccine equity while protecting innovation
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
PhRMA awards $75,000 to fund initiatives to reduce health inequities
Watch: Building trust and enhancing clinical trial diversity
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
Americans 12 years of age and older are eligible for COVID-19 vaccines
PhRMA hosts first stakeholder workshop on clinical trial diversity
Coming together to fight COVID-19: A conversation with Barry Greene, CEO of Sage Therapeutics
A year later: Reflections on the meaning of equity
ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios
Supporting India during the devastating coronavirus surge
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
The Biden Administration allows politics to upend a pragmatic pandemic response
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in community
Reflecting on Mental Health Awareness Month
American leadership on innovation policy is essential to global health progress
Patient safety is at the heart of COVID-19 vaccine R&D
PhRMA member companies share how they are improving clinical trial diversity
ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures
Diversifying clinical trials and fighting disease requires equity and trust
Building confidence in the COVID-19 vaccine through education
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
Intellectual property is the key to vaccine development, manufacturing and technology sharing
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
Fighting variants of COVID-19
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response
Top five issues voters want addressed in the administration’s first 100 days
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
Lessons learned from COVID-19: The way we develop new medicines is changing
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
Growing trend: Increased vaccine confidence
Election insights: Common ground areas to address Americans’ health care concerns
Paper finds gaps in health data are a barrier to health equity
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
Election insights: Voter priorities in the states
Increasing diversity at investigator sites could increase minority participation in clinical trials
Report highlights biopharmaceutical industry’s commitment to D&I
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
Insights from the election: Meeting voters where they are on health care
Coming together to fight COVID-19: A conversation with Kabir K. Nath, President & CEO of Otsuka North America Pharmaceutical Bu
Guest post: How COVID-19 underscores the importance of public confidence in vaccines
Guest Post: Bringing our best to the fight against COVID-19
PhRMA CAREs Grant request for proposals: Addressing racial disparities in medication utilization and adherence
Committing to diversity, equity and inclusion: A call to action for clinical trials
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
Just released: PhRMA members’ new clinical trial diversity principles
Deep dive: The issues that drove the 2020 vote
Understanding the emergency use authorization process for COVID-19 vaccines
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
Voters want to address the real drivers of health care costs for patients and the system
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
Guest Post: Honoring Hispanic Heritage Month by taking action on health equity
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
Leading researchers to spotlight the critical role of biopharmaceutical R&D
Sharing rebates can improve access to medicines and increase health equity
Why the U.S. biopharmaceutical industry is leading the charge against COVID-19
Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
PhRMA will continue to advocate for equity within our industry
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
Three ways the pharmaceutical industry can positively impact health equity
The 2020 We Work for Health Champion Awards showcase the best of our industry
Guest Post: Amgen Foundation stands for equal opportunities in STEM learning
Summer reading in the age of COVID-19
Systemic racism is as real as any disease, and our industry is not immune
The patient perspective navigating COVID-19
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
Executive order threatens R&D when we need it most to fight COVID-19
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem
PhRMA’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states
New initiative to bridge the gap on antimicrobial innovation
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
In combating COVID-19, science is how we get back to normal
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
Guest post: A post-pandemic crisis: The mental toll on America
Guest Post: From lab to jab: Vaccine development to prevent COVID-19
PhRMA awards $100,000 to fund projects that address health inequalities
The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19
What scientific experts are saying about vaccine safety
Guest Post: Honoring Asian and Pacific Islander heritage in the age of COVID-19
IP Explained: Intellectual property system working to combat COVID-19
Guest Post: What will we learn from COVID-19?
Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
What they are saying: Intellectual property protections are critical as we work to defeat COVID-19
Guest Post: Preserving clinical research sites during the coronavirus pandemic
Observing National Minority Health Month in the age of COVID-19
New report shows nearly 260 vaccines in development, including dozens for COVID-19
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
Guest post: Securing the health care supply chain during COVID-19
To the millions affected by COVID-19
New infographic: How we are fighting COVID-19
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
The biopharmaceutical industry’s unique role in responding to COVID-19
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
COVID-19 Response: Supporting the frontline
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
America’s biopharmaceutical companies are working around the clock to beat coronavirus
Guest post: Takeda’s efforts to address COVID-19
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
ICYMI: Continued biopharmaceutical action on COVID-19
Helping those affected by the coronavirus
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
Coronavirus
Health Equity
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month